9 results on '"Krief, Corinne"'
Search Results
2. Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19
- Author
-
Hocini, Hakim, Wiedemann, Aurélie, Blengio, Fabiola, Lefebvre, Cécile, Cervantes-Gonzalez, Minerva, Foucat, Emile, Tisserand, Pascaline, Surenaud, Mathieu, Coléon, Séverin, Prague, Mélanie, Guillaumat, Lydia, Krief, Corinne, Fenwick, Craig, Laouénan, Cédric, Bouadma, Lila, Ghosn, Jade, Pantaleo, Giuseppe, Thiébaut, Rodolphe, Lévy, Yves, Abel, Laurent, Abrous, Amal, Andrejak, Claire, Angoulvant, François, Bachelet, Delphine, Bartoli, Marie, Behilill, Sylvie, Beluze, Marine, Bhavsar, Krishna, Chair, Anissa, Charpentier, Charlotte, Chenard, Léo, Chirouze, Catherine, Couffin-cadiergues, Sandrine, Couffignal, Camille, Castro, Nathalie DE., Debray, Marie-Pierre, Deplanque, Dominique, Descamps, Diane, Diallo, Alpha, Silva, Fernanda Dias DA, Dorival, Céline, Duval, Xavier, Eloy, Philippine, Enouf, Vincent, Esperou, Hélène, Esposito-farese, Marina, Etienne, Manuel, Florence, Aline-Marie, Gaymard, Alexandre, Gigante, Tristan, Gilg, Morgane, Goehringer, François, Guedj, Jérémie, Houas, Ikram, Hoffmann, Isabelle, Hulot, Jean-Sébastien, Jaafoura, Salma, Jamard, Simon, Kafif, Ouifiya, Khalil, Antoine, Lafhej, Nadhem, Laribi, Samira, Le, Minh, Hingrat, Quentin LE., Mestre, Soizic LE., Letrou, Sophie, Lina, Bruno, Lingas, Guillaume, Malvy, Denis, Mentré, France, Mouquet, Hugo, Neant, Nadège, Paul, Christelle, Papadopoulos, Aurélie, Petrov-sanchez, Ventzislava, Peytavin, Gilles, Piquard, Valentine, Picone, Olivier, Rosa-calatrava, Manuel, Rossignol, Bénédicte, Rossignol, Patrick, Roy, Carine, Schneider, Marion, Tardivon, Coralie, Timsit, Jean-François, Tubiana, Sarah, Werf, Sylvie VAN. DER., and Visseaux, Benoit
- Published
- 2023
- Full Text
- View/download PDF
3. Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial.
- Author
-
Lacabaratz, Christine, Durand, Mélany, Wiedemann, Aurélie, Foucat, Emile, Surénaud, Mathieu, Krief, Corinne, Guillaumat, Lydia, Robinson, Cynthia, Luhn, Kerstin, Bockstal, Viki, Thiébaut, Rodolphe, Richert, Laura, and Lévy, Yves
- Subjects
CYTOTOXIC T cells ,VACCINE immunogenicity ,CLINICAL trial registries ,PRINCIPAL components analysis ,VACCINE effectiveness - Abstract
Background The EBL2001 phase 2 trial tested the 2-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine in Europe. Safety and humoral immunogenicity assessments led to European Union market authorization in 2020. Complementary analyses of immune responses are warranted to better characterize vaccine effects. Methods We conducted an ancillary study to analyze changes in the serum and cellular responses. Serum biomarkers of activation/inflammation were evaluated using a Luminex assay. Vaccine-elicited T-cell responses and functions were evaluated by assessing their phenotype, cytokine production, proliferation, and cytotoxic potential. Integrated data analysis was performed through correlation and principal component analysis of serum biomarkers and cellular immune responses. Results Forty-eight volunteers were included. The Ad26.ZEBOV, MVA-BN-Filo vaccine elicited (1) serum increase of inflammatory/activation markers mainly at 1 day after the Ad26.ZEBOV vaccine; and (2) durable EBOV-specific T-cell proliferation and CD8
+ T cells exhibiting a cytotoxic phenotype after Ad26.ZEBOV prime, after MVA-BN-Filo boost, and 6 months postvaccination. Integrated analysis revealed correlations between (1) EBOV-specific CD8+ T-cell proliferation and cytotoxic phenotype; and (2) high EBOV-specific CD8+ T-cell cytotoxic phenotype and low inflammatory marker IL-8 at day 1 postvaccination. Discussion This study provides unique insights into the in vivo contribution of proliferation/cytotoxic CD8+ T cells and inflammation to the Ad26.ZEBOV, MVA-BN-Filo vaccine-induced potency. Clinical Trials Registration. NCT02416453. [ABSTRACT FROM AUTHOR]- Published
- 2025
- Full Text
- View/download PDF
4. Correction to: Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID‑19
- Author
-
Hocini, Hakim, Wiedemann, Aurélie, Blengio, Fabiola, Lefebvre, Cécile, Cervantes‑Gonzalez, Minerva, Foucat, Emile, Tisserand, Pascaline, Surenaud, Mathieu, Coléon, Séverin, Prague, Mélanie, Guillaumat, Lydia, Krief, Corinne, Fenwick, Craig, Laouénan, Cédric, Bouadma, Lila, Ghosn, Jade, Pantaleo, Giuseppe, Thiébaut, Rodolphe, and Lévy, Yves
- Published
- 2023
- Full Text
- View/download PDF
5. Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines
- Author
-
Wiedemann, Aurélie, primary, Surénaud, Mathieu, additional, Hubert, Mathieu, additional, Zaragoza, José-Luis Lopez, additional, Ribeiro, Alexandre, additional, Rodrigues, Cécile, additional, Foucat, Emile, additional, Diombera, Harouna, additional, Krief, Corinne, additional, Schwartz, Olivier, additional, Lelièvre, Jean-Daniel, additional, and Lévy, Yves, additional
- Published
- 2024
- Full Text
- View/download PDF
6. Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients
- Author
-
Wiedemann, Aurélie, Pellaton, Céline, Dekeyser, Manon, Guillaumat, Lydia, Déchenaud, Marie, Krief, Corinne, Lacabaratz, Christine, Grimbert, Philippe, Pantaleo, Giuseppe, Lévy, Yves, Durrbach, Antoine, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), IMRB - 'From pathophysiology towards immune-basedinterventions in HIV infection' [Créteil] (U955 Inserm - UPEC), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Vaccine Research Institute [Créteil, France] (VRI), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université de Lausanne = University of Lausanne (UNIL), Institut Gustave Roussy (IGR), Immunologie intégrative des tumeurs et immunothérapie des cancers (INTIM), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Henri Mondor, Service de néphrologie et transplantation, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Lausanne University Hospital, AP-HP, Hôpital Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique et Maladies Infectieuses 94000 Créteil, France, Department of Nephrology [Le Kremlin-Bicêtre], Institut francilien de recherche en néphrologie et transplantation [Le Kremlin-Bicêtre] (IFRNT), Université Paris-Sud - Paris 11 (UP11)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)-Université Paris-Sud - Paris 11 (UP11)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), and European Project: CoVICIS
- Subjects
immunosuppressive regimen ,immunocompromised ,mRNA vaccine ,[SDV]Life Sciences [q-bio] ,COVID-19 ,General Medicine ,immune responses - Abstract
International audience; Immunocompromised patients have a high risk of death from SARS-CoV-2 infection. Vaccination with an mRNA vaccine may protect these patients against severe COVID-19. Several studies have evaluated the impact of immune-suppressive drug regimens on cellular and humoral responses to SARS-CoV-2 variants of concern in this context. We performed a prospective longitudinal study assessing specific humoral (binding and neutralizing antibodies against spike (S) and T-lymphocyte (cytokine secretion and polyfunctionality) immune responses to anti-COVID-19 vaccination with at least two doses of BNT162b2 mRNA vaccine in stable kidney transplant recipients (KTR) on calcineurin inhibitor (CNI)- or belatacept-based treatment regimens. Fifty-two KTR−31 receiving CNI and 21 receiving belatacept—were enrolled in this study. After two doses of vaccine, 46.9% of patients developed anti-S IgG. Anti-spike IgG antibodies were produced in only 21.4% of the patients in the belatacept group, vs. 83.3% of those in the CNI group. The Beta and Delta variants and, more importantly, the Omicron variant, were less well neutralized than the Wuhan strain. T-cell functions were also much weaker in the belatacept group than in the CNI group. Renal transplant patients have an impaired humoral response to BNT162b2 vaccination. Belatacept-based regimens severely weaken both humoral and cellular vaccine responses. Clinically, careful evaluations of at least binding IgG responses, and prophylactic or post-exposure strategies are strongly recommended for transplant recipients on belatacept-based regimens.
- Published
- 2022
- Full Text
- View/download PDF
7. Differential in vitro inhibitory activity against HIV-1 of alpha-(1-3)- and alpha-(1-6)-D-mannose specific plant lectins : Implication for microbicide development
- Author
-
Balzarini Jan, Krief Corinne, Schols Dominique, Lecerf Maxime, Nasreddine Nadine, Jenabian Mohammad-Ali, Saïdi Hela, and Bélec Laurent
- Subjects
Medicine - Abstract
Abstract Background Plant lectins such as Galanthus nivalis agglutinin (GNA) and Hippeastrum hybrid agglutinin (HHA) are natural proteins able to link mannose residues, and therefore inhibit HIV-target cell interactions. Plant lectins are candidate for microbicide development. Objective To evaluate the activity against HIV of the mannose-specific plant lectins HHA and GNA at the cellular membrane level of epithelial cells and monocyte-derived dendritic cells (MDDC), two potential target cells of HIV at the genital mucosal level. Methods The inhibitory effects of HHA and GNA were evaluated on HIV adsorption to genital epithelial HEC-1A cell line, on HIV transcytosis throughout a monolayer of polarized epithelial HEC-1A cells, on HIV adsorption to MDDC and on transfer of HIV from MDDC to autologous T lymphocytes. Results HHA faintly inhibited attachment to HEC-1A cells of the R5-tropic HIV-1Ba-L strain, in a dose-dependent manner, whereas GNA moderately inhibited HIV adsorption in the same context, but only at high drug doses. Only HHA, but not GNA, inhibited HIV-1JR-CSF transcytosis in a dose-dependent manner. By confocal microscopy, HHA, but not GNA, was adsorbed at the epithelial cell surface, suggesting that HHA interacts specifically with receptors mediating HIV-1 transcytosis. Both plant lectins partially inhibited HIV attachment to MDDC. HHA inhibited more efficiently the transfer of HIV from MDDC to T cell, than GNA. Both HHA and GNA lacked toxicity below 200 μg/ml irrespective the cellular system used and do not disturb the monolayer integrity of epithelial cells. Conclusion These observations demonstrate higher inhibitory activities of the lectin plant HHA by comparison to GNA, on HIV adsorption to HEC-1A cell line, HIV transcytosis through HEC-1A cell line monolayer, HIV adsorption to MDDC and HIV transfer from MDDC to T cells, highlighting the potential interest of HHA as effective microbicide against HIV.
- Published
- 2007
- Full Text
- View/download PDF
8. Differential in vitro inhibitory activity against HIV-1 of alpha-(1-3)- and alpha-(1-6)-D-mannose specific plant lectins : Implication for microbicide development
- Author
-
Saïdi, Hela, primary, Nasreddine, Nadine, additional, Jenabian, Mohammad-Ali, additional, Lecerf, Maxime, additional, Schols, Dominique, additional, Krief, Corinne, additional, Balzarini, Jan, additional, and Bélec, Laurent, additional
- Published
- 2007
- Full Text
- View/download PDF
9. Expression of CD21 is developmentally regulated during thymic maturation of human T lymphocytes.
- Author
-
Fischer, Elizabeth M., Mouhoub, Amal, Maillet, Françoise, Frémeaux-Bacchi, Véronique, Krief, Corinne, Gould, Hannah, Berrih-Aknin, Sonia, and Kazatchkine, Michel D.
- Abstract
CD21, the C3d/CD23/Epstein–Barr virus (EBV), receptor is expressed at low density on cells of the T lineage. Immature thymocytes express CD21 with high density. In the present study, we have analyzed the expression of CD21 during intrathymic maturation of T cells. An intense staining for CD21 was observed at the double-negative stage and at the stage of early acquisition of CD4. CD21 expression was decreased at the double-positive and single-positive stages, to then reach levels similar to those of peripheral blood T cells. Staining of thymus sections showed a bright fluorescent signal on thymocytes entering the thymus in the cortical region. Taking advantage of the immature phenotype of cells expressing high amounts of CD21 (CD21++), we depleted thymocyte suspensions in CD3+ and CD8+ cells to study the properties of CD21 on this cell subset. Triggering of CD21 with its ligands iC3b, CD23 and anti-CD21 mAb did not alter the proliferative response of thymocytes to IL-7, and did not induce the differentiation of early cells into CD4+CD8+ thymocytes. Immunoprecipitation did not reveal any molecule associated with CD21 that could play a signaling role in thymocytes. Finally, EBV induced a down-regulation of CD21 and an up-regulation of CD1 in CD21++ thymocytes. Taken together, our observations demonstrate a regulated expression of CD21 on human thymocytes and suggest that the CD21++ subset may be a target for EBV. We further suggest that CD21 on early thymocytes acts as a ligand for CD23-expressing cells in the thymus. [ABSTRACT FROM PUBLISHER]
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.